Head-to-head comparison
Key differences
- Mechanism: BPC-157 activates the FAK-paxillin signaling pathway and upregulates growth hormone receptors; TB-500 upregulates actin to promote cell migration.
- Origin: BPC-157 is a 15-amino-acid fragment derived from human gastric juice; TB-500 is a synthetic fragment of thymosin beta-4, a 43-amino-acid peptide found throughout human tissues.
- Routes: BPC-157 can be administered subcutaneously, intramuscularly, or orally; TB-500 is typically administered subcutaneously or intramuscularly only.
- Dosing frequency: BPC-157 is commonly dosed twice daily (250–500 mcg); TB-500 is typically dosed twice weekly (2–5 mg) during loading.
- Primary research focus: BPC-157 is most studied for tendon, ligament, and GI tract repair; TB-500 is most studied for wound healing and cardiac tissue recovery.
- Evidence base: BPC-157 has over 100 preclinical studies; TB-500 has a smaller but established body of preclinical research plus extensive veterinary use in racehorses.
- Legal status: Both are currently under FDA reclassification review as part of the 14-peptide RFK Jr. initiative.
The verdict
Neither BPC-157 nor TB-500 is universally superior. BPC-157 may be more relevant for GI tract and tendon injuries based on available preclinical data, while TB-500 shows particular promise in wound healing and cardiac recovery. Many protocols combine both peptides for their complementary mechanisms. Neither has completed human clinical trials, so all evidence remains preclinical.
Frequently asked questions
BPC-157 and TB-500 are frequently combined in recovery protocols, a combination known as the Wolverine stack. They target tissue repair through different pathways—BPC-157 via the FAK-paxillin pathway and TB-500 via actin upregulation—which may produce complementary effects. No human clinical trials have studied this combination.
BPC-157 has more preclinical research specifically on tendon repair, including rat studies showing 72% accelerated healing of transected Achilles tendons. TB-500 promotes general tissue repair via cell migration but has less tendon-specific data. Many protocols use both together.
Both peptides have an estimated half-life of approximately 4 hours. However, their dosing schedules differ: BPC-157 is typically dosed twice daily, while TB-500 is typically dosed twice weekly at higher amounts per injection.
Both peptides are currently under FDA reclassification review as part of the 14-peptide initiative. They were previously available from research chemical suppliers; most US vendors ceased sales in 2025–2026.
BPC-157 has a larger body of published preclinical research, with over 100 studies. TB-500 has fewer published studies but benefits from extensive real-world use in veterinary medicine, particularly in racehorses. Neither has completed human clinical trials.